

Supplementary Table 1. Baseline characteristics of reports on vaccine-associated ischemic stroke adverse events

Variables	Value (n=5,843)
Region reporting	
African Region	10 (0.17)
Region of the Americas	2,976 (50.93)
South-East Asia Region	37 (0.63)
European Region	2,663 (45.58)
Eastern Mediterranean Region	52 (0.89)
Western Pacific Region	105 (1.80)
Reporting year	
2010–2019	41 (0.70)
2020–2023	5,802 (99.30)
Reporter qualification	
Health Professional	1,627 (27.85)
Non-Health Professional	4,216 (72.15)
Studies	
Study-related	5,813 (99.49)
Non-study related	30 (0.51)
Sex	
Male	2,947 (50.44)
Female	2,851 (48.79)
Unknown	45 (0.77)
Age, years	
18–44	500 (8.56)
45–64	1,469 (25.14)
65–74	1,054 (18.04)
≥75	1,432 (24.51)
Unknown	1,388 (23.75)
Delay (TTO), days	
Median (Q1–Q3)	1 (1–1)
Drug class	
Influenza vaccines	61 (1.04)
COVID-19 mRNA vaccines	4,587 (78.50)
Ad5-vectored COVID-19 vaccines	1,098 (18.79)
Inactivated whole-virus COVID-19 vaccines	55 (0.94)
Others*	42 (0.72)
Fatal outcomes	
Alive	2,905 (49.72)
Fatal	244 (4.18)
Unknown	2,694 (46.11)
Single drug suspected	5,843 (100)

Values are presented as n (%) unless otherwise indicated.

TTO, time to onset.

*Others: anthrax, brucellosis, cholera, dengue vaccines, diphtheria, Ebola, encephalitis, *Haemophilus influenzae* type b, hepatitis A, hepatitis B, leptospirosis, measles, meningococcal, mumps, papillomavirus, pertussis, plague, pneumococcal, polio, rabies, rotavirus diarrhea, rubella, smallpox, tetanus toxoids, tuberculosis, typhoid, typhus, varicella zoster and yellow fever vaccines.